miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib

Table 1

Clinicopathological characteristics of patients.

	Screening cohort		Validation cohort
	Responders	Nonresponders	Responders	Nonresponders
Gender
Male	6 (75%)	8 (100%)	34 (77.3%)	11 (57.9%)
Female	2 (15%)	0 (0%)	10 (22.7%)	8 (42.1%)
Age
Median	64	64	66	66
Range	40–80	53–73	41–84	45–84
Histology
Papillary carcinoma	1 (12.5%)	1 (12.5%)	3 (6.8%)	3 (5.8%)
Clear cell carcinoma	7 (87.5%)	7 (87.5%)	41 (93.2%)	16 (84.2%)
Grade
1	0 (0%)	0 (0%)	6 (13.6%)	0 (0%)
2	2 (25%)	3 (37.5%)	11 (25%)	5 (26.4%)
3	5 (62.5%)	3 (37.5%)	13 (29.5%)	7 (36.8%)
4	1 (12.5%)	2 (25%)	5 (11.4%)	7 (36.8%)
Unknown	0 (0%)	0 (0%)	9 (20.5%)	0 (0%)
Response to sunitinib according to RECIST criteria
Complete response	0 (0%)	0 (0%)	1 (2.3%)	0 (0%)
Partial response	6 (75%)	0 (0%)	19 (43.2%)	0 (0%)
Stable disease	2 (25%)	0 (0%)	24 (54.5%)	0 (0%)
Progressive disease	0 (0%)	8 (100%)	0 (0%)	19 (100%)